Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Other Events
Item 8.01 Other Events.
  On March 2, 2017, Foundation Medicine, Inc. (the Company) issued
  a press release announcing that it has received payment from
  Palmetto GBA, the Companys Medicare Administrative Contractor in
  North Carolina, for its FoundationOne comprehensive genomic
  profiling assay when used in the clinical course of care for
  individuals in the United States with Stage IIIB/IV non-small
  cell lung cancer (NSCLC) who meet the eligibility requirements
  under Palmetto GBAs Local Coverage Determination. Payment for all
  claims processed to date by Palmetto has been made based upon the
  allowable rate of $3,416 per test. The full text of the press
  release is filed as Exhibit 99.1 to this Current Report on Form
  8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | 
| 99.1 | 
        Press release of Foundation Medicine, Inc. dated March 2, 2017.  | 
 About Foundation       Medicine, Inc. (NASDAQ:FMI) 
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.	Foundation       Medicine, Inc. (NASDAQ:FMI) Recent Trading Information 
Foundation       Medicine, Inc. (NASDAQ:FMI) closed its last trading session up +0.50 at 26.05 with 265,620 shares trading hands.
                


